Switching from Elavil (Amitriptyline) to Remeron (Mirtazapine) for Stomach Issues
Switch to mirtazapine using a 2-4 week cross-taper, as mirtazapine has significantly fewer gastrointestinal side effects than amitriptyline and is specifically associated with increased appetite rather than nausea or GI distress. 1, 2
Rationale for the Switch
Mirtazapine is an excellent choice for patients experiencing stomach issues on tricyclic antidepressants:
- Mirtazapine has the fewest gastrointestinal side effects among commonly used antidepressants, being associated only with increased appetite rather than nausea, vomiting, diarrhea, or abdominal pain 2
- Amitriptyline causes significant anticholinergic effects including dry mouth, constipation, and GI disturbances, which mirtazapine largely avoids 3, 4
- Mirtazapine promotes appetite and weight gain rather than causing GI upset, making it particularly suitable for patients with stomach complaints 3, 5
Cross-Taper Protocol
Use a gradual 2-4 week cross-taper rather than abrupt switching:
- Start mirtazapine 7.5-15 mg at bedtime while maintaining current amitriptyline dose 3, 5
- Gradually reduce amitriptyline by 25% every 3-7 days while increasing mirtazapine to 15-30 mg 1, 5
- Complete the amitriptyline taper over 2-4 weeks to minimize withdrawal symptoms 1, 5
- Do not abruptly discontinue amitriptyline at any point during the transition 1, 5
Critical Safety Monitoring During the Switch
Monitor for serotonin syndrome during the overlap period when both medications are present:
- Watch for mental status changes, neuromuscular hyperactivity (tremor, rigidity, myoclonus), and autonomic instability (tachycardia, diaphoresis, hyperthermia) 5
- Symptoms typically arise within 24-48 hours if they occur, though risk is low with this combination 1, 5
- Assess patient status within 1-2 weeks of initiating the switch and regularly thereafter 6
Mirtazapine Dosing Considerations
Target therapeutic dosing appropriately:
- Start at 7.5-15 mg at bedtime, then increase to 30 mg after 1-2 weeks if tolerated 3, 5
- Maximum dose is 45 mg daily if needed for adequate response 3, 5
- Sedation is paradoxically more common at lower doses (<15 mg), so don't remain at subtherapeutic doses 7, 4
- Allow 6-8 weeks at therapeutic dose before assessing full response 6, 5
Expected Benefits Beyond GI Tolerability
Mirtazapine offers additional advantages relevant to this patient:
- Improves sleep disturbances and anxiety symptoms commonly associated with depression 3, 8, 9
- May have faster onset of antidepressant action compared to SSRIs, with benefits seen as early as 1 week 7, 8
- Equivalent antidepressant efficacy to tricyclics like amitriptyline 3, 8, 4
Common Pitfalls to Avoid
Key errors that compromise the switch:
- Do not stop amitriptyline abruptly—this causes withdrawal symptoms including rebound cholinergic effects 1
- Do not combine with MAOIs—ensure no MAOI use within 14 days before or after this switch 5
- Do not remain at 7.5 mg mirtazapine long-term, as this subtherapeutic dose causes more sedation without adequate antidepressant effect 7
- Monitor for agranulocytosis if fever, sore throat, or infection develops—check complete blood count immediately 5
Alternative Strategy: Augmentation
Consider maintaining both medications rather than completing the full switch:
- Evidence shows equivalent efficacy and safety between switching to mirtazapine versus augmenting with mirtazapine 1
- If the patient improves during the overlap period, combination therapy may be continued 1
- This decision should be guided by tolerability during the cross-taper and patient preference 1
Monitoring Treatment Response
Assess response systematically:
- Approximately 38% of patients do not achieve adequate response with antidepressant switches, so close follow-up is essential 1
- If no adequate response after 6-8 weeks at therapeutic mirtazapine dose, modify treatment strategy 6
- Monitor for suicidal ideation closely during the first 1-2 months, particularly in the first 1-2 weeks 6, 5